Oncology Reprint Collection, CHLA

Items are arranged in order of publication date.
Please click on the "PDF" buttons to download the files.

Drug Development
Back to Top

  - "A Fluorescence Digital Image Microscopy System for Quantifying Relative Cell Numbers in Tissue Culture Plates" by Robert T. Proffitt, James V. Tran, and C. Patrick Reynolds, in : Cytometry, 24:204-213 (1996).

  - "Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)-retinamide in Neuroblastoma Cell Lines" by Barry J. Maurer, Leonid S. Metelitsa, Robert C. Seeger, Myles C. Cabot, C. Patrick Reynolds, Journal of the National Cancer Institute, Vol. 91, No. 13, July 7, 1999, Reports, pp 1138 - 1146

  - "Differentiating Agents in Pediatric Malignancies: Retinoids in Neuroblastoma" by C. Patrick Reynolds, MD, PhD, in : Current Oncology Reports, 2:511-518, 2000.

  - "Synergistic cytotoxicity in solid tumor cell lines between N-(4-Hydroxyphenyl)retinamide and modulators of ceramide metabolism" by Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP, J Natl Cancer Inst, 92:1897-1908, 2000.

  - "Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide" by Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ, Medical Pediatric Oncology, 35:597-602, 2000.

  - "Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression" by Anderson, CP, Keshelava N, Satake N, Meek WH, Reynolds CP, Medical Pediatric Oncololgy, 35:659-662, 2000.

  - "Is there a role for retinoids in therapy of minimal residual disease in neuroblastoma?" by Matthay KK and Reynolds CP, Br J Cancer, 83:1121-1123, 2000.

  - "N-(4-Hydroxyphenyl)retinamide Elevates Ceramide in Neuroblastoma Cell Lines by Coordinate Activation of Serine Palmitoyltransferase and Ceramide Synthase 1" by Hongtao Wang, Barry J. Maurer, C. Patrick Reynolds, and Myles C. Cabot, Cancer Research 61, 5102 – 5105, July 1, 2001.

  - "Cytotoxic agents Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy" by CPAnderson and CP Reynolds, Bone Marrow Transplantation (2002) 30, 135–140

  - "N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines,but not to non-malignant lymphocytes" by PH O’Donnell, W-X Guo, CP Reynolds and BJ Maurer, Leukemia (2002) 16, 902–910

  - "Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary" - Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith, Clinical Cancer Research Vol. 8, 3646–3657, December 2002

  - "Ceramide synthesis and metabolism as a target for cancer therapy" by Reynolds, C. P., Maurer, B. J., and Kolesnick, R. N., Cancer Lett., 206: 169-180, 2004

  - "Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues." by Vratilova, J., Frgala, T., Maurer, B. J., and Reynolds, C.P., J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 808: 125-130, 2004

  - "In vitro testing of chemosensitivity in physiological hypoxia." by Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.,Methods Mol.Med., 110: 87-100, 2005

  - "DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy." by Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P., Methods Mol.Med., 110: 139-153, 2005

  - "Evaluating response to antineoplastic drug combinations in tissue culture models" by Reynolds, C. P. and Maurer, B. J., Methods Mol.Med., 110: 173-183, 2005

  - "Assessing growth and response to therapy in murine tumor models." by Reynolds, C. P., Sun, B. C., DeClerck, Y. A., and Moats, R. A., Methods Mol.Med., 111: 335-350, 2005

  - "Tirapazamine cytotoxicity for neuroblastoma is p53 dependent" by Yang, B. and Reynolds, C. P., Clin.Cancer Res., 11: 2774-2780, 2005

Drug Resistance
Back to Top

  - "Drug Resistance Patterns of Human Neuroblastoma Cell Lines Derived from Patients at Different Phases of Therapy" by Nino Keshelava, Robert C. Seeger, Susan Groshen, and C. Patrick Reynolds, in : Cancer Research, 58:5396-5405, December 1, 1998.

  - "Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines" by Keshelava N, Groshen S, Reynolds CP, Cancer Chemotherapy and Pharmacology, 45:1-8, 2000.

  - "p53 mutations and loss of p53 function confer multi-drug resistance in neuroblastoma" by Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP, Medical Pediatric Oncology, 35:563-568, 2000.

  - "Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors" by Goto H., Choi MR, Keshelava N, Reynolds CP, in : Medical Pediatric Oncology, 35:619-622, 2000.

  - "Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines" by Nino Keshelava, Juan J. Zuo, Ping Chen, Sitara N. Waidyaratne, Marian C. Luna, Charles J. Gomer, Timothy J. Triche, and C. Patrick Reynolds, in : Cancer Research, 61, 6185–6193, August 15, 2001.

© Childrens Hospital Los Angeles (2002-2006)  Disclaimer

01066

Drug Development	Back to Top
-	"A Fluorescence Digital Image Microscopy System for Quantifying Relative Cell Numbers in Tissue Culture Plates" by Robert T. Proffitt, James V. Tran, and C. Patrick Reynolds, in : Cytometry, 24:204-213 (1996).
-	"Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)-retinamide in Neuroblastoma Cell Lines" by Barry J. Maurer, Leonid S. Metelitsa, Robert C. Seeger, Myles C. Cabot, C. Patrick Reynolds, Journal of the National Cancer Institute, Vol. 91, No. 13, July 7, 1999, Reports, pp 1138 - 1146
-	*"Differentiating Agents in Pediatric Malignancies: Retinoids in Neuroblastoma" by C. Patrick Reynolds, MD, PhD, in : Current Oncology Reports, 2:511-518, 2000.*
-	"Synergistic cytotoxicity in solid tumor cell lines between N-(4-Hydroxyphenyl)retinamide and modulators of ceramide metabolism" by Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP, J Natl Cancer Inst, 92:1897-1908, 2000.
-	"Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide" by Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ, Medical Pediatric Oncology, 35:597-602, 2000.
-	"Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression" by Anderson, CP, Keshelava N, Satake N, Meek WH, Reynolds CP, Medical Pediatric Oncololgy, 35:659-662, 2000.
-	*"Is there a role for retinoids in therapy of minimal residual disease in neuroblastoma?" by Matthay KK and Reynolds CP, Br J Cancer, 83:1121-1123, 2000.*
-	"N-(4-Hydroxyphenyl)retinamide Elevates Ceramide in Neuroblastoma Cell Lines by Coordinate Activation of Serine Palmitoyltransferase and Ceramide Synthase 1" by Hongtao Wang, Barry J. Maurer, C. Patrick Reynolds, and Myles C. Cabot, Cancer Research 61, 5102 – 5105, July 1, 2001.
-	"Cytotoxic agents Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy" by CPAnderson and CP Reynolds, Bone Marrow Transplantation (2002) 30, 135–140
-	"N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines,but not to non-malignant lymphocytes" by PH O’Donnell, W-X Guo, CP Reynolds and BJ Maurer, Leukemia (2002) 16, 902–910
-	"Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary" - Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith, Clinical Cancer Research Vol. 8, 3646–3657, December 2002
-	*"Ceramide synthesis and metabolism as a target for cancer therapy" by Reynolds, C. P., Maurer, B. J., and Kolesnick, R. N., Cancer Lett., 206: 169-180, 2004*
-	"Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues." by Vratilova, J., Frgala, T., Maurer, B. J., and Reynolds, C.P., J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 808: 125-130, 2004
-	*"In vitro testing of chemosensitivity in physiological hypoxia." by Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.,Methods Mol.Med., 110: 87-100, 2005*
-	"DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy." by Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P., Methods Mol.Med., 110: 139-153, 2005
-	*"Evaluating response to antineoplastic drug combinations in tissue culture models" by Reynolds, C. P. and Maurer, B. J., Methods Mol.Med., 110: 173-183, 2005*
-	*"Assessing growth and response to therapy in murine tumor models." by Reynolds, C. P., Sun, B. C., DeClerck, Y. A., and Moats, R. A., Methods Mol.Med., 111: 335-350, 2005*
-	*"Tirapazamine cytotoxicity for neuroblastoma is p53 dependent" by Yang, B. and Reynolds, C. P., Clin.Cancer Res., 11: 2774-2780, 2005*
Drug Resistance	Back to Top
-	"Drug Resistance Patterns of Human Neuroblastoma Cell Lines Derived from Patients at Different Phases of Therapy" by Nino Keshelava, Robert C. Seeger, Susan Groshen, and C. Patrick Reynolds, in : Cancer Research, 58:5396-5405, December 1, 1998.
-	*"Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines" by Keshelava N, Groshen S, Reynolds CP, Cancer Chemotherapy and Pharmacology, 45:1-8, 2000.*
-	*"p53 mutations and loss of p53 function confer multi-drug resistance in neuroblastoma" by Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP, Medical Pediatric Oncology, 35:563-568, 2000.*
-	"Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors" by Goto H., Choi MR, Keshelava N, Reynolds CP, in : Medical Pediatric Oncology, 35:619-622, 2000.
-	"Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines" by Nino Keshelava, Juan J. Zuo, Ping Chen, Sitara N. Waidyaratne, Marian C. Luna, Charles J. Gomer, Timothy J. Triche, and C. Patrick Reynolds, in : Cancer Research, 61, 6185–6193, August 15, 2001.